You have free access to this content

Cancer

Cover image for Cancer

1 May 2008

Volume 112, Issue 9

Pages 1871–2101

  1. Commentary

    1. Top of page
    2. Commentary
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development (pages 1871–1873)

      Maurie Markman

      Version of Record online: 4 MAR 2008 | DOI: 10.1002/cncr.23385

      A rational framework is proposed for the conduct of clinical cancer research in the developing world that permits all members of these societies to benefit from the efforts.

  2. Editorials

    1. Top of page
    2. Commentary
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Surgical staging and cervical cancer : After 30 years, have we reached a conclusion? (pages 1874–1876)

      David H. Moore

      Version of Record online: 17 MAR 2008 | DOI: 10.1002/cncr.23386

      The study reported by Gold and colleagues in this issue of Cancer emerges as the first comparative study to clearly suggest a benefit of surgical staging over clinical staging. The importance of confirming their findings through a prospective, randomized trial may be offset by declining disease incidence and other scientific priorities.

    2. You have free access to this content
      Renal sparing surgery for children with bilateral Wilms tumor (pages 1877–1878)

      Michael Ritchey

      Version of Record online: 7 MAR 2008 | DOI: 10.1002/cncr.23387

      Renal-sparing surgery is feasible in children with bilateral Wilms tumor even if large bilateral masses are present. Careful monitoring of renal function after surgery is necessary in these patients.

  3. Review Articles

    1. Top of page
    2. Commentary
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Systemic therapy for metastatic colorectal cancer : Current questions (pages 1879–1891)

      Dan S. Zuckerman and Jeffrey W. Clark

      Version of Record online: 13 MAR 2008 | DOI: 10.1002/cncr.23409

      • original image

      In the last decade, many advances have served to double the median length of survival for patients with metastatic colorectal cancer. In this article, the authors discuss questions that have arisen out of so much progress, examining the interface between cytotoxic therapy and therapy that targets angiogenesis and the epidermal growth factor receptor, the role of chemotherapy-free intervals, and the timing of chemotherapy for those patients with potentially resectable liver metastases.

    2. You have free access to this content
      A review : Obesity and screening for breast, cervical, and colorectal cancer in women (pages 1892–1904)

      Sarah S. Cohen, Rachel T. Palmieri, Sarah J. Nyante, Daniel O. Koralek, Sangmi Kim, Patrick Bradshaw and Andrew F. Olshan

      Version of Record online: 24 MAR 2008 | DOI: 10.1002/cncr.23408

      For this review, the authors evaluated the evidence regarding associations between obesity and screening behavior for breast, cervical, and colorectal cancers among women in the U.S. Adherence to cancer screening was associated with obesity for cervical and breast cancer with some variation observed by race, although the evidence linking obesity and colorectal cancer screening behavior was inconclusive.

  4. Original Articles

    1. Top of page
    2. Commentary
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Prognostic significance of HER-2 status in women with inflammatory breast cancer (pages 1905–1911)

      Shaheenah Dawood, Kristine Broglio, Yun Gong, Wei-Tse Yang, Massimo Cristofanilli, Shu-Wan Kau, Funda Meric-Bernstam, Thomas A. Buchholz, Gabriel N Hortobagyi, Ana M. Gonzalez-Angulo and for the Inflammatory Breast Cancer Research Group

      Version of Record online: 25 FEB 2008 | DOI: 10.1002/cncr.23350

      • original image

      Inflammatory breast cancer (IBC), a rare, aggressive subset of locally advanced breast cancer, accounts for approximately 1% to 6% of all breast cancer cases. In the current study, the prognostic impact of HER-2 status on survival outcomes of patients with IBC was investigated.

    2. You have free access to this content
      Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines (pages 1912–1922)

      Geoff Delaney, Jesmin Shafiq, Genevieve Chappell and Michael Barton

      Version of Record online: 4 MAR 2008 | DOI: 10.1002/cncr.23384

      • original image
      • original image
      • original image
      • original image
      • original image

      An evidence-based benchmark was developed for proportions of all patients with screen-detected breast cancer who should receive breast-conserving surgery, mastectomy, radiotherapy, chemotherapy, and/or hormonal therapy by reviewing evidence-based treatment guidelines and merging the indications for the various treatments with epidemiologic data. The resulting optimal utilization rates were then compared with actual treatment rates reported by the screening unit.

    3. You have free access to this content
      Role of resection margins in patients treated with breast conservation surgery (pages 1923–1931)

      Giorgio Zavagno, Elena Goldin, Roberto Mencarelli, Giovanni Capitanio, Paola Del Bianco, Renato Marconato, Simone Mocellin, Giorgia Marconato, Valentina Belardinelli, Francesca Marcon and Donato Nitti

      Version of Record online: 7 MAR 2008 | DOI: 10.1002/cncr.23383

      • original image
      • original image

      Resection margins status is commonly used to decide whether reexcision is indicated in breast cancer patients who have undergone breast conservation surgery. Whereas frankly involved margins indicate further surgery, close margins are not representative of the surrounding tissue status and cannot be considered an indication for reexcision.

    4. Gastrointestinal Disease
      You have free access to this content
      UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma (pages 1932–1940)

      Chun-Yu Liu, Po-Min Chen, Tzeon-Jye Chiou, Jin-Hwang Liu, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang and Wei-Shu Wang

      Version of Record online: 25 FEB 2008 | DOI: 10.1002/cncr.23370

      • original image
      • original image
      • original image
      • original image

      It has been established that the uridine-diphosphoglucuronosyl transferase 1A1 (UGT1A1)*28 polymorphism, through an extra thymine-adenine (TA) repeat in the promoter, reduces UGT1A1 enzyme activity and the glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan. Results in this retrospective study suggest that this polymorphism may be a key determinant for predicting irinotecan-induced severe toxicities without affecting treatment outcome for patients with metastatic colorectal carcinoma.

    5. Genitourinary Disease
      You have free access to this content
      Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy (pages 1941–1948)

      David Palma, Scott Tyldesley, Tom Pickles and for the Prostate Cohort Outcomes Initiative

      Version of Record online: 13 MAR 2008 | DOI: 10.1002/cncr.23388

      • original image

      In 277 patients with intermediate- and high-risk prostate cancer who were treated with radiotherapy and androgen-deprivation therapy, a high pretreatment prostate-specific antigen (PSA) velocity was associated with distant metastasis and prostate cancer-specific mortality, but not with local recurrence. A high pretreatment PSA velocity may signify the presence of occult metastatic disease.

    6. You have free access to this content
      Cardiovascular risk in long-term survivors of testicular cancer (pages 1949–1953)

      David J. Vaughn, Steven C. Palmer, Joseph R. Carver, Linda A. Jacobs and Emile R. Mohler

      Version of Record online: 13 MAR 2008 | DOI: 10.1002/cncr.23389

      • original image

      Long-term survivors of testicular cancer (TC) treated with chemotherapy have an increased cardiovascular risk. Compared with chemotherapy-naive TC survivors, those treated with cisplatin-based chemotherapy demonstrate objective evidence of endothelial injury and dysfunction.

    7. Gynecologic Oncology
      You have free access to this content
      Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma : A Gynecologic Oncology Group study (pages 1954–1963)

      Michael A. Gold, Chunqiao Tian, Charles W. Whitney, Peter G. Rose and Rachelle Lanciano

      Version of Record online: 13 MAR 2008 | DOI: 10.1002/cncr.23400

      • original image
      • original image
      • original image

      Patients with cervical cancer who were participating in 1 of 3 Phase III Gynecologic Oncology Group trials who had negative para-aortic lymph node status determined by surgical sampling were compared with patients who had para-aortic lymph node status determined radiographically. The results indicated that surgical exclusion had a significant prognostic impact.

    8. You have free access to this content
      CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility (pages 1964–1973)

      Hiroshi Hirata, Yuji Hinoda, Naoko Okayama, Yutaka Suehiro, Ken Kawamoto, Nobuyuki Kikuno, Joseph T Rabban, Lee May Chen and Rajvir Dahiya

      Version of Record online: 4 MAR 2008 | DOI: 10.1002/cncr.23392

      • original image

      Polymorphisms of estrogen-metabolizing genes are risk factors for endometrial cancer.

    9. Head and Neck Disease
      You have free access to this content
      Smoking and risk of parotid gland tumors : A nationwide case-control study (pages 1974–1982)

      Siegal Sadetzki, Bernice Oberman, Lori Mandelzweig, Angela Chetrit, Tehila Ben-Tal, Avital Jarus-Hakak, Shay Duvdevani, Elisabeth Cardis and Michael Wolf

      Version of Record online: 24 MAR 2008 | DOI: 10.1002/cncr.23393

      Assessment of the association between smoking and development of parotid gland tumors indicated a significant increase in the risk of Warthin tumor but no association with pleomorphic adenoma. Although a possible indication of increased risk of malignant tumors was observed, the small number of patients limited the conclusiveness of the results.

    10. Hematologic Malignancies
      You have free access to this content
      Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse (pages 1983–1991)

      Nobuko Hijiya, Clinton F. Stewart, Yinmei Zhou, Dario Campana, Elaine Coustan-Smith, Gaston K. Rivera, Mary V. Relling, Ching-Hon Pui and Amar Gajjar

      Version of Record online: 4 MAR 2008 | DOI: 10.1002/cncr.23395

      A regimen comprising single-agent topotecan given with a standard 3-drug combination was effective in inducing remission in pediatric patients with relapsed acute lymphoblastic leukemia.

    11. You have free access to this content
      Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation (pages 1992–2001)

      Mohamed Sorror, Barry Storer, Brenda M. Sandmaier, David G. Maloney, Thomas R. Chauncey, Amelia Langston, Richard T. Maziarz, Michael Pulsipher, Peter A. McSweeney and Rainer Storb

      Version of Record online: 29 FEB 2008 | DOI: 10.1002/cncr.23375

      • original image
      • original image
      • original image
      • original image
      • original image

      Comorbidity and performance status provide independent prognostic information and combining measures of both refines risk-stratification for nonmyeloablative hematopoietic cell transplantation outcomes.

    12. Hepatobiliary Disease
      You have free access to this content
      Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma (pages 2002–2010)

      Fan Wu, Si-Yu Liu, Yi-Ming Tao, Di-Peng Ou, Feng Fang and Lian-Yue Yang

      Version of Record online: 7 MAR 2008 | DOI: 10.1002/cncr.23396

      • original image
      • original image
      • original image
      • original image

      This study was the first to the authors' knowledge demonstrating decreased expression levels of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) in human hepatocellular carcinoma (HCC). The results indicated that patients who had HCC with low Mus81 expression levels had either poorer disease-free survival or poorer overall survival than patients who had high Mus81 expression levels, suggesting that Mus81 may serve as a prognostic marker in HCC.

    13. Lung Disease
      You have free access to this content
      Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status (pages 2011–2020)

      S.-H. Ignatius Ou, Jason A. Zell, Argyrios Ziogas and Hoda Anton-Culver

      Version of Record online: 24 MAR 2008 | DOI: 10.1002/cncr.23397

      • original image
      • original image

      Low socioeconomic status and being unmarried are 2 factors that led to lower surgical rates for patients with stage I nonsmall cell lung cancer (NSCLC) because of lower acceptance of surgery by patients and their families, less likelihood that patients would be offered surgery by physicians, and higher comorbidities of the patients. These observations partially explain why low socioeconomic status and being unmarried are 2 independent poor prognostic factors for survival in patients with stage I NSCLC.

    14. You have free access to this content
      Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older (pages 2021–2029)

      George R. Simon, Martine Extermann, Alberto Chiappori, Charles C. Williams, Mubeena Begum, Rachna Kapoor, Eric B. Haura, Roohi Ismail-Khan, Michael J. Schell, Scott J. Antonia and Gerold Bepler

      Version of Record online: 25 FEB 2008 | DOI: 10.1002/cncr.23360

      • original image
      • original image

      Docetaxel combined with gefitinib is active and well tolerated in chemonaive patients with advanced nonsmall-cell lung cancer who are aged ≥70 years. Median survivals were 22.8 months in women and 4.8 months in men, indicating that female sex-specific confirmatory clinical trials with this regimen are warranted.

    15. Melanoma
      You have free access to this content
      Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease (pages 2030–2037)

      Daniel A. Anaya, Yan Xing, Lei Feng, Xuelin Huang, Luis H. Camacho, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield and Janice N. Cormier

      Version of Record online: 4 MAR 2008 | DOI: 10.1002/cncr.23399

      • original image
      • original image
      • original image

      In this retrospective review, the authors found that the use of adjuvant high-dose interferon for patients with stage III melanoma was associated with improved recurrence-free survival, with the most striking benefit noted for patients with stage IIIA disease.

    16. Neuro-Oncology
      You have free access to this content
      Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma (pages 2038–2045)

      Marc C. Chamberlain, Denice D. Wei-Tsao, Deborah T. Blumenthal and Michael J. Glantz

      Version of Record online: 24 MAR 2008 | DOI: 10.1002/cncr.23404

      The primary objective of this prospective phase 2 study of CPT-11 (irinotecan) in adult patients with recurrent, temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival. CPT-11 demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent AA, all of whom had failed on prior temozolomide chemotherapy.

    17. You have free access to this content
      Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas (pages 2046–2051)

      Doo-Sik Kong, Jung-Il Lee, Kwan Park, Jong Hyun Kim, Do-Hoon Lim and Do-Hyun Nam

      Version of Record online: 13 MAR 2008 | DOI: 10.1002/cncr.23402

      • original image
      • original image
      • original image
      • original image

      Although temozolomide plus radiotherapy has recently been shown to improve the outcome for newly diagnosed glioblastoma patients, the treatment of recurrent malignant gliomas still remains challenging. The objective of the current prospective cohort study was to determine the efficacy of stereotactic radiosurgery as a salvage treatment in patients with recurrent malignant gliomas.

    18. Sarcoma
      You have free access to this content
      Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients (pages 2052–2059)

      Mark L. Kayton, Ruby Delgado, Klaus Busam, Hiram S. Cody III, Edward A. Athanasian, Daniel Coit and Michael P. La Quaglia

      Version of Record online: 13 MAR 2008 | DOI: 10.1002/cncr.23403

      • original image

      Sentinel lymph node biopsy for pediatric soft-tissue tumors can be performed safely, and the results can alter treatment decisions both for children with rhabdomyosarcoma and adolescents with breast cancer. In patients with nonrhabdomyosarcoma soft-tissue sarcomas, no positive sentinel lymph nodes and no lymph node basin recurrences were observed, despite the lack of lymph node basin irradiation or formal lymph node dissection. These data should prompt the prospective study of sentinel lymph node biopsy as a modality that might help guide the administration or withholding of regional therapy among pediatric patients with nonrhabdomyosarcoma soft-tissue sarcoma.

    19. Discipline

      Pediatric Oncology
      You have free access to this content
      The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor : The St. Jude Children's Research Hospital experience: 1999–2006 (pages 2060–2070)

      Andrew M. Davidoff, Dana W. Giel, Deborah P. Jones, Jesse J. Jenkins, Matthew J. Krasin, Fredric A. Hoffer, Mark A. Williams and Jeffrey S. Dome

      Version of Record online: 24 MAR 2008 | DOI: 10.1002/cncr.23406

      • original image
      • original image
      • original image
      • original image
      • original image

      Nephron-sparing surgery for children with bilateral Wilms tumor generally is technically feasible. This approach, when combined with adjuvant therapy, provides the opportunity to preserve renal function while maintaining a high probability of cure.

    20. You have free access to this content
      Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia : A report from the Childhood Cancer Survivor Study (pages 2071–2079)

      Daniel A. Mulrooney, Douglas C. Dover, Suwen Li, Yutaka Yasui, Kirsten K. Ness, Ann C. Mertens, Joseph P. Neglia, Charles A. Sklar, Leslie L. Robison, Stella M. Davies and and the Childhood Cancer Survivor Study

      Version of Record online: 7 MAR 2008 | DOI: 10.1002/cncr.23405

      • original image
      • original image

      Little is known about the late medical and social effects experienced by survivors of childhood and adolescent acute myeloid leukemia (AML). This analysis of 272 5-year AML survivors revealed favorable long-term survival. However, survivors had ongoing medical complications, and they had lower social attainments compared with a sibling control group but similar to those among the general population.

    21. Symptom Control and Palliative Care
      You have free access to this content
      Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (pages 2080–2087)

      Jon D. Herrington, Adam D. Jaskiewicz and Juhee Song

      Version of Record online: 7 MAR 2008 | DOI: 10.1002/cncr.23364

      • original image
      • original image
      • original image

      The combination of palonosetron and aprepitant has been shown to be effective in the prevention of acute and delayed emesis. In a randomized, double-blind, placebo-controlled, pilot trial, single-dose aprepitant 125 mg orally plus palonosetron 0.25 mg intravenously and dexamethasone displayed similar effectiveness as the traditional 3-day aprepitant regimen in preventing acute and delayed chemotherapy-induced emesis.

    22. Translational Research
      You have free access to this content
      Epithelial to mesenchymal transition in head and neck squamous carcinoma : Association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features (pages 2088–2100)

      Mahitosh Mandal, Jeffery N. Myers, Scott M. Lippman, Faye M. Johnson, Michelle D. Williams, Suresh Rayala, Kazufumi Ohshiro, David I. Rosenthal, Randal S. Weber, Gary E. Gallick and Adel K. El-Naggar

      Version of Record online: 7 MAR 2008 | DOI: 10.1002/cncr.23410

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The results of the current study demonstrate that p-Src up-regulation, E-cadherin underexpression, and vimentin acquisition by tumor cells to be key events in the epithelial to mesenchymal transition and aggressive features of head and neck squamous carcinomas.

  5. Erratum

    1. Top of page
    2. Commentary
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Erratum (page 2101)

      Version of Record online: 17 MAR 2008 | DOI: 10.1002/cncr.23480

      • original image

SEARCH

SEARCH BY CITATION